Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Nations stockpile mpox vaccine amid rising geopolitical fears
9 Jul 2025, 14:48BAVA.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Bavarian Nordic A/S – Notice Convening Ordinary General Meeting 28 Mar 2019
Bavarian Nordic Awards Restricted Stock Units to Executive Management21 Mar 2019
Bavarian Nordic Announces Annual Report 201821 Mar 2019
Bavarian Nordic Announces FDA Delay in the Review of the Biologics License Application for MVA-BN Smallpox Vaccine11 Mar 2019
Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen21 Feb 2019
Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine18 Jan 2019
Bavarian Nordic A/S - Articles of Association
Search

Danish vaccine maker Bavarian Nordic will supply an undisclosed European country with its smallpox and mpox vaccine under a new contract valued at over 200 million Danish Krone, the company announced Wednesday.

Bavarian Nordic sells vaccine voucher for $160 million
20 Jun 2025, 17:26BAVA.CONASDAQ Copenhagen

Danish vaccine company Bavarian Nordic has entered an agreement to sell a Priority Review Voucher for a total of $160 million, the company said Wednesday.

  • Previous
  • 1
  • 2
  • 3
  • Next
7 Jan 2019
Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine21 Dec 2018
Bavarian Nordic - Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program13 Nov 2018
Bavarian Nordic Announces Interim Results for the First Nine Months of 20189 Nov 2018
Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers2 Nov 2018
Henrik Juuel Joins Bavarian Nordic as Chief Financial Officer1 Nov 2018
  • Previous
  • 1
  • More pages
  • 26
  • 27
  • 28
  • More pages
  • 78
  • Next
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
Filings
927